Current technologies enable measurements and analyses that are deployed to create and test hypotheses about human disease. But what are the events that we cannot yet measure, analyze or test?
Check out Think/Do Tank: Solving Unmet Needs at the Edge of Disease Profiling, an interdisciplinary, high-risk/high-return discussion intended to uncover promising new collaborations between the ASU School of Molecular Sciences and TGen (Translational Genomics Research Institute).
You may also watch the event remotely.
Attendees can also register on-site. Refreshments will be provided. If you plan to park, parking instructions will be sent prior to the event.
The three sessions will feature different lead speakers from TGen who will frame the topic in clinical terms, and several researchers from ASU and TGen will then briefly cover concepts to stimulate the discussion.
2–3 p.m. Single-Cell Biology of Human Disease
Session Lead: Harshil Dhruv, PhD, Assistant Professor, TGen
New technology enables disassembly of tissues to single cells for individual genomic profiling and protein characterization, often uncovering insight into mechanisms of disease and novel treatment approaches. Tissue dissociation loses reference to adjacencies, nearest-neighbor inferences, and syncytial effects. Can innovative strategies from the Molecular Sciences bring functional and anatomical measurements to understand and treat human disease?
3–4 p.m. Intrinsic and Extrinsic Biomarkers
Session Lead: Patrick Pirrotte, PhD, Director, Center for Proteomics, TGen
Biofluids are comprised of complex mixtures of molecules, a select few are a direct representation of health or disease. The range of the scale of proteins in most biofluids confounds discovery of precise biomarkers. Are there Molecular Science approaches to probe or to discover human pathology with greater sensitivity, precision and intentionality?
4–5 p.m. State/Rate of Change in Disease Systems
Session Lead: Dave Engelthaler, PhD, Director, Programs & Operations, TGen
Our evolving understanding of the dynamic nature of the microbiome necessitates the development of new approaches to closely monitor these changes over the course of chronic infectious diseases. This provides for more timely and dynamic profiling of key features, such as the changing pathobiome and resistome, which will allow for more precise medical responses. We will discuss the real-world impact of regular targeted sequencing of chronic lung infections, from cystic fibrosis to tuberculosis.